Immune checkpoint inhibitors (ICIs) in the recent times have transformed the landscape of the management of many solid tumors. Unfortunately, many immune-related adverse effects are associated with ICIs, which lead to a negative outcome in cancer treatment. We present a case of a 63-year-old female with metastatic adenocarcinoma of unknown origin, who developed celiac disease during the course of treatment with pembrolizumab. Association of celiac disease with this form of immunotherapy has never been documented before.
Keywords: cancer immunotherapy; celiac disease; gluten-free diet; immune check point inhibitor colitis; immune check point inhibitor induced celiac disease; immune checkpoint inhibitors; immune-related adverse effects; ipilimumab; nivolumab; pembrolizumab.
Copyright © 2021, Sethi et al.